Cardiometabolic syndrome and sarcopenic obesity are overlapping public health problems in older adults that increase the risk of cardiovascular mortality and type 2 diabetes.
Understanding the pathophysiologic mechanisms of sarcopenic obesity is important for elucidating the relationship between cardiometabolic syndrome and cardiovascular mortality and morbidity in older adults.
The aging of the world's population is a major contributor to the growing prevalence of the cardiometabolic syndrome (CMS) because older persons are more affected by the constellation of cardiovascular risk factors that constitute the syndrome. The prevalence of CMS has been related to the increasing prevalence of obesity, which is growing progressively even among older age groups. Indeed, obesity and aging are 2 overlapping mounting public health problems. It is currently accepted that CMS predicts cardiovascular mortality and/or the development of type 2 diabetes mellitus, and this is also true in studies including older persons. CMS is further complicated by modifications in body composition and fat redistribution during aging; older adults are at higher risk for developing central obesity and sarcopenia or sarcopenic obesity, a condition characterized by an important reduction in lean body mass associated with obesity, linked to an increased production of inflammatory adipokines that may alter insulin sensitivity and muscle mass and strength. A better understanding of the pathophysiologic mechanisms of sarcopenic obesity may help to elucidate the complex relationship between CMS and mortality/morbidity in older adults.
Domínguez et al. (Fri,) conducted a review in Cardiometabolic syndrome and sarcopenic obesity. Cardiometabolic syndrome and sarcopenic obesity are overlapping public health problems in older adults that increase the risk of cardiovascular mortality and type 2 diabetes.